Inventor
MASTELLER EMMA
US12 patents
⚠️ This page may combine multiple inventors who share the name “MASTELLER EMMA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
FIVE PRIME THERAPEUTICS INC
11 patentsUS9765147B2Sep 19, 2017
Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
FIVE PRIME THERAPEUTICS INC25 citations93
US11155615B2Oct 26, 2021
Anti-ROR1 antibodies
FIVE PRIME THERAPEUTICS INC13 citations85
US10618967B2Apr 14, 2020
Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
FIVE PRIME THERAPEUTICS INC5 citations83
US10221244B2Mar 5, 2019
Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
FIVE PRIME THERAPEUTICS INC10 citations83
US10221243B2Mar 5, 2019
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
FIVE PRIME THERAPEUTICS INC4 citations68
US11559583B2Jan 24, 2023
Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer
FIVE PRIME THERAPEUTICS INC0 citations62
US11566076B2Jan 31, 2023
Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
FIVE PRIME THERAPEUTICS INC0 citations61
US10982001B2Apr 20, 2021
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
FIVE PRIME THERAPEUTICS INC1 citations61
US10975153B2Apr 13, 2021
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
FIVE PRIME THERAPEUTICS INC1 citations57
US10822421B2Nov 3, 2020
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
FIVE PRIME THERAPEUTICS INC0 citations48
US11421034B2Aug 23, 2022
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
FIVE PRIME THERAPEUTICS INC0 citations46